By Dean Seal

Shares of Soligenix Inc. gained 17% to 65 cents in premarket trading Tuesday after the company said regulators had cleared an investigational new drug application for a clinical trial examining its psoriasis treatment.

The company said the Food and Drug Administration had cleared the application for a Phase 2a trial designed to evaluate SGX302 as a topically applied treatment for mild to moderate psoriasis.

The trial will be a randomized, double-blind and placebo-controlled study of up to 32 adults with stable psoriasis covering between 2% and 30% of their bodies. Treatment will last for up to 18 weeks, Soligenix said.

Patient enrollment is expected to begin in the fourth quarter of 2022.

Write to Dean Seal at dean.seal@wsj.com

(END) Dow Jones Newswires

June 28, 2022 08:12 ET (12:12 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.